Kraig Biocraft Laboratories Inc (KBLB) |
|
Price: $0.0960
$0.00
2.236%
|
Day's High:
| $0.0966
| Week Perf:
| -0.41 %
|
Day's Low: |
$ 0.09 |
30 Day Perf: |
1.05 % |
Volume (M): |
595 |
52 Wk High: |
$ 0.16 |
Volume (M$): |
$ 57 |
52 Wk Avg: |
$0.10 |
Open: |
$0.09 |
52 Wk Low: |
$0.06 |
|
|
Market Capitalization (Millions $) |
100 |
Shares
Outstanding (Millions) |
1,038 |
Employees |
8 |
Revenues (TTM) (Millions $) |
- |
Net Income (TTM) (Millions $) |
-4 |
Cash Flow (TTM) (Millions $) |
-2 |
Capital Exp. (TTM) (Millions $) |
0 |
Kraig Biocraft Laboratories Inc
Kraig Biocraft Laboratories, Inc. is a corporation organized under the laws
of Wyoming on April 25, 2006. We were organized to develop high strength fibers
using recombinant DNA technology, for commercial applications in both the specialty
fiber and technical textile industries. Specialty fibers are engineered for
specific uses that require exceptional strength, flexibility, heat resistance
and/or chemical resistance. The specialty fiber market is exemplified by two
synthetic fiber products: aramid fibers and ultra-high molecular weight polyethylene
fiber. The technical textile industry involves products for both industrial
and consumer products, such as filtration fabrics, medical textiles (e.g., sutures
and artificial ligaments), safety and protective clothing and fabrics used in
military and aerospace applications (e.g., high-strength composite materials).
While scientists have been able to replicate the proteins that are the building
blocks of spider silk, the technological barrier that has stymied production
until now has been the inability to form these proteins into a fiber with the
desired mechanical characteristics and to do so in a cost effective manner.
We have licensed the right to use the patented genetic sequences and genetic
engineering technology developed in university laboratories. The Company has
been working collaboratively with university laboratories to develop fibers
with the mechanical characteristics of spider silk. We are applying this proprietary
genetic engineering technology to domesticated silkworms, which are already
the most efficient commercial producers of silk.
Our technology builds upon the unique advantages of the domesticated silkworm
for this application. The silkworm is ideally suited to produce recombinant
protein fiber because it is already an efficient commercial and industrial producer
of protein based polymers. Forty percent (40%) of the caterpillars’ weight
is devoted to the silk glands. The silk glands produce large volumes of protein,
called fibroin, which are then spun into a composite protein thread (silk).
We are working to use our genetic engineering technology to create recombinant
silk polymers. On September 29, 2010, we jointly announced with the University
of Notre Dame the success of our collaborative research with Notre Dame in creating
approximately twenty different strains of transgenic silkworm which produce
recombinant silk polymers. In April 2011, we entered into a licensing agreement
with Sigma-Aldrich which provides us the use of Sigma-Aldrich’s zinc finger
technology to accelerate and enhance our product development.
A part of our intellectual property portfolio is the exclusive right to use
certain patented spider silk gene sequences in silkworm. Under the Exclusive
License Agreement with the University of Wyoming, we have obtained certain exclusive
rights to use numerous genetic sequences which are the subject of US patents.
The introduction of the gene sequence, in the manner employed by us, results
in a germline transformation and is therefore self-perpetuating. This technology
is in essence a protein expression platform which has other potential applications
including diagnostics and pharmaceutical production.
Company Address: 2723 South State St. Suite 150 Ann Arbor 48104 MI
Company Phone Number: 619-8066 Stock Exchange / Ticker: KBLB
|
|
Customers recorded net loss |
Customers recorded net loss |
|
|
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Kraig Biocraft Laboratories Inc
Financial News Report: Kraig Biocraft Laboratories Inc Surges in Q2 2024 Kraig Biocraft Laboratories Inc, a leading developer of spider silk-based fibers, has reported its financial performance for the period between January and March 31, 2024. The company experienced significant growth in revenue, while also reducing its net loss compared to the previous year. During the mentioned period, KBLB achieved a per-share value of $0.00, which remained consistent with the year prior. However, it is notable that there was no growth nor decline in this metric in comparison to the preceding reporting period. In terms of revenue, the company witnessed a substantial surge to $0.03 million, as opposed to $0.00 million during the same reporting period the previous year. This growth reflects the company's continued efforts to expand its market share and improve its financial standing. However, sequentially, the revenue fell by -18.681% from the prior period, which might be indicative of short-term challenges faced by the company.
|
Kraig Biocraft Laboratories Inc
Kraig Biocraft Laboratories Inc (KBLB) is a biotechnology company that specializes in genetic engineering and developing innovative materials using spider silk. With a focus on commercializing spider silk technologies, the company aims to create stronger and more versatile materials for various industrial applications. In the fiscal time-frame from July to September 2023, Kraig Biocraft Laboratories Inc reported a revenue of $0.049196 million. While this might seem relatively low, it is noteworthy considering the company's focus on research and development, which often generates revenue in the later stages of product development.
|
Kraig Biocraft Laboratories Inc
Kraig Biocraft Laboratories Inc, a prominent player in the Chemical Manufacturing industry, has recently released its financial results for the second quarter of the 2023 earnings season. The company reported a revenue of $0.022638 million during this period, showcasing its ability to generate consistent sales and maintain a steady market position. However, these financial results also indicate a slight decline in net deficit compared to the same reporting period last year. Kraig Biocraft Laboratories Inc posted a net deficit of $-0.589 million, which is a modest improvement from the $-1.038 million deficit recorded in the corresponding period a year ago. While this may be perceived by some as a negative outcome, it is essential to consider the broader context in order to form a more comprehensive analysis of the company's financial health. The Chemical Manufacturing industry is a complex and often volatile sector. Companies operating within it face numerous challenges, such as fluctuating demand, evolving regulations, and intense competition. Against this backdrop, Kraig Biocraft Laboratories Inc's ability to reduce its net deficit and limit losses should be acknowledged as a positive achievement. It reflects the company's efforts to streamline operations, control costs, and find ways to improve its bottom line.
|
Kraig Biocraft Laboratories Inc
Chemical Manufacturing company has reported a revenue of $0.004269 million in the financial time-frame ending March 31 2023. This is a modest growth in revenue compared to the previous reporting period. The company's financials have been on an upward trend in recent times. On the other hand, Kraig Biocraft Laboratories Inc has reported a net deficit of $-0.567 million, which is a significant improvement compared to a deficit of $-1.047 million in the same reporting period a year ago. This indicates that the company has made significant efforts to improve its financials and cut down on losses.
|
Per Share |
Current |
Earnings (TTM) |
-0 $ |
Revenues (TTM) |
0 $
|
Cash Flow (TTM) |
- |
Cash |
0 $
|
Book Value |
-
|
Dividend (TTM) |
0 $ |
|
Per Share |
|
Earnings (TTM) |
-0 $
|
Revenues (TTM) |
0 $ |
Cash Flow (TTM) |
- |
Cash |
0 $
|
Book Value |
- |
Dividend (TTM) |
0 $ |
|
|
|
|